SITS MOST, SITS Stroke-Monitoring Study, was performed with the aim to assess the safety and efficacy of intravenous alteplase as thrombolytic therapy within the first 3 hours of onset of acute ischaemic stroke.
The SITS-MOST study made a global impact on stroke treatment guidelines confirming safety and efficacy for the IVT-routine in less than 4.5 hours.